Phase 2
Completed N=22
Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Source: ClinicalTrials.gov NCT00581854 ↗Enrolled (actual)
22
Serious AEs
36.4%
Results posted
Jul 2014
Primary outcomePrimary: Complete Response Rate to Induction Therapy — 64 percentage of participants
Summary
rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Response Rate to Induction Therapy |
64 | — |
Eligibility Criteria
Inclusion Criteria
- Untreated mantle cell lymphoma
Exclusion Criteria
- Pregnant or breast feeding
Data sourced from ClinicalTrials.gov (NCT00581854). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.